Body Extension and the Law: Medical Devices, Intellectual Property, Prosthetics and Marginalisation (Again)

Shawn H.E. Harmon

Honorary Fellow, School of Law, University of Edinburgh, Scotland

Abbe Brown

Professor in Intellectual Property Law, School of Law, University of Aberdeen, Scotland

Sita Popat

Professor in Performance and Technology, School of Performance and Cultural Industries, University of Leeds, England

Sarah Whatley

Professor of Dance, Centre for Dance Research, Coventry University, England

Rory O’Connor

Charterhouse Professor of Rehabilitation Medicine, Faculty of Medicine and Health, University of Leeds, England

Corresponding author: Abbe Brown, abbe.brown@abdn.ac.uk, School of Law, Taylor Building, Old Aberdeen, AB24 3UB @IGFTowardAccess orcid.org/0000-0002-2222-4537.

This work was supported by the Wellcome Trust Seed Award “Identity, Governance and Bodily Extensions” under Grant 201515/Z/16/Z (application reference UNS17486)

There are no financial conflicts of interest or benefits arising from this research.

Word count: (including footnotes) : 
Body Extension and the Law: Medical Devices, Intellectual Property, Prosthetics and Marginalisation (Again)

This interdisciplinary paper, drawing on empirical and doctrinal research regarding artificial limbs and digital avatars, analyses two concepts which are argued to be core to the person – integrity and identity. From the perspective of a person who is a prosthetic user, the paper then evaluates the extent to which two legal regimes which are highly relevant to prosthetics, medical devices regulation (and its delivery) and intellectual property (and its power), engage with the person, integrity and identity with a focus on approaches taken to authority and control. The paper criticises the meaning which law generates regarding the person. It calls for new approaches to be taken by the legal regimes explored to the person, identity and integrity; and for a new multifaceted interdisciplinary driven approach to the person.

Keywords: Person; integrity; identity; intellectual property; medical devices.

1. Introduction

Human beings – persons bounded in a physiological form – sit at the heart of many of our governance frameworks, both moral and legal. The law often focuses, however, on particular outcomes rather than the person; law leaves mostly unaddressed much that might be important to the identity, boundaries and expression of the person. At the same time, the ability of the law to effectively govern the increasingly technology-entangled person is more and more challenged, by the growing complexity and fragmentation of the person in a postmodern and technology-saturated society. Whereas the person has traditionally been positioned in terms of a binary (human v. nature, human v. machine, individual v. group, man v. woman, non-disabled v. disabled),¹ there is a

¹ This is an approach much criticised by followers of the affirmative model of disability,
growing recognition that the person is in fact an ‘assemblage’\(^2\) – a variably integrated collection of physical/physiological, material/mechanical, and virtual/digital elements in fluid relation to one another.

Given the above, we (an interdisciplinary group, from law, performance and medicine) explore law as it relates to the person as extended or modified by physical prosthetics. Our focus is on artificial limbs applied due to an absence caused by congenital condition, physical illness or injury, or personal choice.\(^3\) Our analysis draws heavily on doctrinal legal research, practical medical clinical experiences, and a small but highly relevant set of semi-structured interviews and focus groups. The work is grounded in ‘Identity and Governance of Bodily Extensions: The Case of Prosthetics and Avatars’, an interdisciplinary project funded by the Wellcome Trust,\(^4\) and also, as will be noted, on which broadly focuses on what people can do; and indeed by supporters of the social model which sees disability as the restrictions imposed on individuals by society through the social and physical barriers that characterise common interactions and built environments, rather than on how individuals may be ‘impaired’ John Swain and Sally French “Conclusions: Some Reflections on Key Questions” in John Swain and French, S. (eds.) Disability on Equal Terms (London: Sage, 2008) in contrast to the more traditional medical model of disability, which sees disability (which would include the absence of a limb) as a physiological and functional problem to be remedied or otherwise managed so that the individual can better operate and be accepted in a society not designed for them – see Union of the Physically Impaired Against Segregation, Fundamental Principles of Disability (London: London UPIAS, 1976). For a critique on how medical law and bioethics has engaged with disability, see Alicia Ouellette Bioethics and Disability: Toward a Disability-Conscious Bioethics (Cambridge: CUP, 2011), and Shawn Harmon “The Invisibility of Disability: Using Dance to Shake from Bioethics the Idea of ‘Broken Bodies’” (2015) 29 Bioethics 488-498; the social model has achieved significant recognition in policy and law-making, notably the Convention on the Rights of Persons with Disabilities (2006).


\(^3\) Elizabeth Wicks The State and the Body: Legal Regulation of Bodily Autonomy (Oxford: Hart, 2016), which, at 107, discusses bodily modification. Also note the sociological work of the late Debra Gimlin: https://www.researchgate.net/profile/Debra_Gimlin/publications?pubType=article. It is with affection and respect that Brown expresses deep sadness that she will be unable to continue their conversations on this issue.

\(^4\) See http://www.pci.leeds.ac.uk/research/featured-research-projects/identity-and-governance-of-bodily-extensions-the-case-of-prosthetics-and-avatars/. In the context of this project, we
previous empirical research in the disability and digital settings.

Our intent is to uncover the extent to which laws in general, and two specific legal regimes in particular – medical devices ("MD") and intellectual property ("IP") - are sensitive to, or appropriately reflect, the reality of persons who use these particular extensions. The first regime was chosen because prosthetics are medical devices, the marketing and provision of which typically require regulatory approval with respect to quality and safety standard compliance. The second regime was chosen because prosthetics or their components can be the results of innovation and creativity; as such IP rights (particularly patent, design and copyright) can be obtained, claimed and exercised. Technology can also make it increasingly easy to copy the work of others, thus potentially infringing IP rights while enhancing personal experiences.\(^5\) We argue that these regimes have the potential to impact directly on prosthetic development, allocation, and use; they empower or marginalise prosthetic users, a group already long and widely discriminated against;\(^6\) and they contribute to how prosthetic users are constructed and treated more

\(^5\) For example, 3D printing allows individuals to build/print devices in their home with very little oversight, and in the process to copy IP-enclosed products: with a focus on technology, see Adam Thierer and Adam Marcus “Guns, Limbs, and Toys: What Future for 3D Printing” (2016) 17 Minnesota Journal of Law, Science & Technology 805-854; with a focus on legal pathways, see

\(^6\) Paul Abberley “The Concept of Oppression and the Development of a Social Theory of
broadly in society.

In Section 2, we identify and explore two concepts that, however vague and contested they may be, are central to ‘meaning-making’ in the disability and prosthetics context, namely ‘identity’ and ‘integrity’. These provide a lens through which we can examine the law and its adequacy. In Section 3, we examine in more depth the extent to which the MD and IP frameworks engage with prosthetic limbs. In Section 4, we discuss the level of engagement within each of the two legal frameworks to identity and integrity, highlighting the other concepts that are favoured. In the MD regulatory and also clinical contexts, Section 4.1.1 explores safety, a focus on patients, development and risk; and Section 4.1.2 analyses budgets, delivery, and the opportunity for court action. Section 4.2 explores the IP context, critiquing the impact of IP rights in terms of their existence and power. We then argue in Section 4.3 argues that the control and authority which results from these legal regimes has inadequate regard to identity and integrity, particularly in the light of some empirical conclusions, and proposals for change are made. We conclude (in Section 5) that a new, multifaceted approach to the person is warranted. Some initial and innovative contributions are made regarding the extent to which the law, through these two regimes specifically, could change to empower prosthetic users, facilitate their


7 We acknowledge that there may well be other concepts of significance to prosthetic-users, but our research highlights these as particularly important, and they potentially have some resonance with the frameworks we are exploring.

8 Note separation discussion in an analysis piece Shawn H. E. Harmon, Abbe Brown, Sita Popat, Sarah Whatley, and Rory O’Connor, "Struggling to be Fit: Identity, Integrity, and the Law", (2017) 14:2 SCRIPTed 326 https://script-ed.org/?p=3411 DOI: 10.2966/scrip.140217.326 regarding the location of these concepts in the broader legal landscape offering an overview of the extent to which they are noticed and how they are understood.
capacity to act and engage with society, and engage with the concepts of integrity and identity in ways that are positive and enabling.


Meanings are the cognitive categories that make up our view of reality.\(^9\) The making or taking of meaning is critical to human life, because humans have a natural tendency to make meaning out of their experiences, and out of, and for, their lives.\(^10\) Indeed it has been argued that:

The most fundamental aspect of a human social setting is that of meanings. These are the linguistic categories that make up a participant’s view of reality and with which actions are defined. Meanings are also referred to by social analysts as culture, norms, understandings, social reality, and definitions of the situation, typifications, ideology, beliefs, worldview, perspective or stereotypes. Terms such as these share a common focus with humanly constructed ideas that are consciously singled out as important aspects of reality. Meanings are transbehavioral in the sense that they do more than describe behavior – they define, justify, and otherwise interpret it as well.\(^11\)

---

\(^9\) Charles Chen “On exploring meanings: Combining humanistic and career psychology theories in counselling” (2001) 14 *Counselling Psychology Quarterly* 317-331.  
While meanings can be broad (e.g., ideologies or philosophies) or narrow (e.g., attached to defined aspects of the human existence or a person’s life and experience), they all shape narrative identity, or that sense of personal unity and purpose and place which is derived from diverse experiences and interactions. In short, however broad or narrow, or whether derived from human relations or contact with social systems, meanings have impacts on the individual. Moreover, these impacts are often psycho-socially significant (i.e., they are important both to disposition and psychological wellbeing, on the one hand, and to social reality and standing, on the other).

Previous interdisciplinary research undertaken by the authors in the context of elite/professional dance made and performed by disabled dancers suggests that the concepts of ‘identity’ (including the potential for a person to have and to choose multiple identities) and ‘integrity’ are particularly important for meaning-making in the prosthetics setting. These concepts are properly, indeed unavoidably, viewed as holding psycho-social significance for prosthetic users; through their conduct, relationships, experiences, and points of contact with the built and social worlds, prosthetic users (indeed all of us) give meaning to these concepts. In turn, these concepts influence, for better or for worse, our understanding(s) of ourselves and each other, the world, and our place in that world.

13 See the InVisible Difference Project (http://www.invisibledifference.org.uk/), an AHRC-funded project that sought to extend thinking around the making, status, ownership and value of work by contemporary dance choreographers, focusing specifically on that made and performed by disabled dance artists; and the Projecting Performance Project, an AHRC-funded project that examined methods of digital extension to the technical operator’s body in theatrical performance contexts: Sita Popat & Scott Palmer, “Embodied Interfaces: Dancing with Digital Sprites” (2008) Digital Creativity 19:2, 125-137.
As such, we consider each briefly below.

As should be apparent from any interaction with the world, ‘identity’ (and ‘identities’, although for present purpose it will mainly be discussed in the singular) is critical to the person. Identity is, however, a contested and multifaceted concept, bearing both subjective and objective elements.\textsuperscript{14} With respect to the former, it is used to describe a variety of phenomena, including core personal values and interests, and self-perceptions. With respect to the latter, it encompasses public statuses that might be assigned at birth or later, and third-party descriptions. Thus, identities can be constructed through individual and fluid narrative practices, or imposed externally and set more permanently through formal institutions.\textsuperscript{15} As such, it has been argued that individuation is a process in which individuals express an identity to the extent permitted by those with whom they are in communication and partnership; and that we construct our identity in large part by learning from, and drawing on, the perspectives of others toward our qualities and abilities.\textsuperscript{16} However, the social entanglement that characterises identity renders us vulnerable to ‘disrespect’, which can not only upset our personal narrative, but also expose us to physical risk, and so to a loss of our second concept - integrity.

The concept of ‘integrity’ has a strong moral character, and is closely linked to

dignity, which refers to the unity and wellbeing of the person.\textsuperscript{17} It can be both measured against and infringed by various forms of personal insult. As such, the constitution of human integrity (including physical integrity), which is particularly relevant to the prosthetics setting because of its links with questions of perceived wholeness, is dependent on the experience of ‘intersubjective recognition’ (i.e., it depends on receiving approval and respect from others).\textsuperscript{18} This again links back to identity. What is not often appreciated, is that (physical) integrity can be achieved in the absence of conformity to the social norm (i.e., to the normatively constructed whole, or healthy, or idealised body). Indeed, physical perfection is often cited as a damaging myth,\textsuperscript{19} and physical normality as a socio-political tool that too often distracts us from the variety and malleability of the human form; and from the fact that different forms of embodiment or ways of being can be just as exemplary of integrity as others despite their traditional association with non-wholeness or disability.\textsuperscript{20} In other words, one can achieve a sense of (physical) integrity within a wide array of embodiments that do not comply with the metrics of the normative body,\textsuperscript{21} and so the notion of integrity is potentially an empowering concept. Integrity is also critical to the above-mentioned notion of body as assemblage. It is the integrity or unity that defines the assemblage, and sets it apart from just a collection of parts.\textsuperscript{22}

\textsuperscript{17} For more on dignity, see Charles Foster \textit{Human Dignity in Bioethics and Law} (Oxford: Hart, 2011).


\textsuperscript{20} Nikki Sullivan “Integrity, Mayhem, and the Question of Self-Demand Amputation” (2005) 19 \textit{Continuum: Journal of Media & Culture Studies} 325-333.


\textsuperscript{22} Manuel DeLanda \textit{A New Philosophy of Society: Assemblage Theory and Social Complexity} (London: Continuum, 2006). DeLanda argues that the whole and the parts exist simultaneously on the ontological plane; the properties of the whole are contingent upon the relationship of the parts with each other, and to some extent vice-versa, which means that the
Further, the concepts of identity and integrity are linked in both subtle and complex, and even inconsistent, ways to the individual’s prosthesis and lived experience. This is not only borne out by our own research introduced above, where dancers held multiple and situationally-driven feelings toward, and relationships with, their prosthesis;\(^{23}\) but also by research involving amputees, which has shown that the use of a prosthesis can be associated with the perception of an effective extension of the arm,\(^ {24}\) and by brain-imaging research, which has shown cortical reorganisation on the part of amputees after use of assistive tools.\(^ {25}\) Neuroscientific studies have also demonstrated that, under certain conditions, the brain is able to treat a tool as part of the body.\(^ {26}\) Similarly, research into digital gaming and performance has shown that people readily extend their presence and identity into virtual worlds via embodiment of their avatars; and that they were enabled and restricted by the technology made available to them, in some cases creating new identities\(^ {27}\) - which may or may not be bipedal or humanoid. For example, the human player might choose a different gender, or to become an animal not

\(^{23}\) For example, some of our participants slipped quite readily back and forth between talking about their prosthetic legs as inanimate objects, and as parts of their own bodies.


found in real world nature and/or to have new traits, such as the ability to fly.\textsuperscript{28}

All told, it would seem that body representation, which is critical to identity formation, is plastic, capable of incorporating salient external objects, tools and assistive devices.\textsuperscript{29} The reason or objective for the prosthesis (as rehabilitative or functional replacement, as tool, as aesthetic addition through choice, or as something else), together with other external factors (like its appearance, capabilities, or who controls it and how) may also influence how the prosthesis is perceived within the bodily assemblage. These can give rise to a greater sense of embeddedness and ownership, thereby undermining characterisations of ‘artificiality’.\textsuperscript{30} Parenthetically, the objectives associated with it (as tool, replacement, or other) may also (or ought to) have different implications for the


design and functional parameters of the prosthesis. 31

In summary, identity is shaped in part by physiology. And while society imposes bipedal uprightness as the physical norm and creates social and environmental pressures to conform, 32 prosthetic users can nonetheless achieve a sense of physical integrity regardless of the particulars of their embodiment. They may feel whole and internally harmonious despite their divergence from the ‘normal’ parameters of wholeness and idealised embodiment which may be imposed by society. Further, the users’ identity and sense of integrity will almost certainly be influenced by the prosthesis; and so, even if a prosthesis is developed in, and designed for, the rehabilitative setting, their characterisation as a rehabilitative tool or mere functional replacement may not be appropriate. 33 The prosthesis may be additionally desired for its constitutive function and its influence on individuation. Indeed, the prosthesis might be inculcated into the individual’s personal narrative such that one’s sense of ‘ownership’ over it (not necessarily in a legal sense) might be comparable to that of the usual physiological body part it is meant to replace. Given the above, it seems clear that how key specific legal frameworks approach both these core meaning-making concepts, and prosthetics more specifically, is important.

3 Legal Frameworks and their approaches to prosthetics

So informed, we are now equipped to explore in greater depth the principles and the rules of the two legal frameworks (MD and IP) in an effort to evaluate their worldview. This discussion could sit alongside a broader system of laws and norms such as property law[34] and contract law[35] (both of which engage with ownership of the physical prosthesis), information control law (which engages with the structure and use of the prosthesis),[36] tax law (which engages with status)[37] and how well the law respects and facilitates our diversity, notably through human rights.[38] However, these issues must lie


[37] Amoena (UK) Ltd v The Commissioners for HM Revenue and Customs [2011] UKFTT 675 (TC) regarding a mastectomy bra; this discusses mass production, individual need, substitutability for the body - rather than disability.

outside the scope of this paper. As a preliminary point, we will explore the extent to which the frameworks explicitly recognise prosthetics as within their remit. This may impact on how cognisant they are of the particularities of the prosthetics environment.

The MD regime will be explored on the basis of a 2017 EU Regulation of 2017 that will come into effect in 2020. It preserves many of the key features of the existing regime, and once in force, must be applied in its entirety across the EU - as with so many issues, the approach to be taken in the UK after Brexit remains to be seen. The EU Regulation defines a ‘medical device’ as any instrument, apparatus, appliance, implant or other article intended by the manufacturer to be used, alone or in combination, for human beings for one or more of a number of specific medical purposes - one of which is the ‘replacement or modification of the anatomy or of a physiological or pathological process or state’. Such devices can only be ‘placed on the market or put into service’ if they comply with the EU Regulation, and are supplied and properly installed, maintained, and used in accordance with their intended purpose. In short, a wide range of artefacts are captured, including prosthetics. Their availability is contingent on compliance with the regime established.

In contrast, IP laws focus on whether the requirements are met for a right to exist,

---


40 EU Regulation (n5), art 2.1(1).

41 EU Regulation (n5), art 5.1.
rather on the uses of the underlying subject matter. IP law is found in national\(^{42}\) and EU\(^{43}\) law (again for the UK there is the Brexit uncertainty), under the umbrella of international treaties like the TRIPS Agreement,\(^{44}\) within the World Trade Organisation.\(^{45}\) For an IP right to exist, there needs to be an invention, the non-functional appearance of a product or an original piece of work which meets the thresholds for (respectively), the patent, design, or copyright to exist. For patents, the invention needs to be new and also inventive as compared to common general knowledge.\(^ {46}\) For registered design, the appearance needs to be new and of individual character, with the overall impression on the informed user differing from the overall impression of others.\(^ {47}\) For a UK unregistered design the shape or configuration of whole or part of the article is not to be common place.\(^ {48}\) For copyright (which is also an unregistered right) the works needs to be original in the sense of not being copied from the work of another,\(^ {49}\) and to come within a relevant category – key examples relevant here are literary works for drawings,\(^ {50}\) sculptures and graphic work irrespective of artistic quality\(^ {51}\) and works of artistic craftsmanship.\(^ {52}\) There are


\(^{44}\) Agreement on Trade-Related Aspects of Intellectual Property Rights, Annex 1 C to the WTO Agreement (TRIPS)

\(^{45}\) See WTO website \url{https://www.wto.org} (last accessed 13 September 2017).

\(^{46}\) Patents Act 1977, ss1-3.

\(^{47}\) Registered Designs Act 1949, ss1(2), 1B(1) and (3), 1C and Community Design Regulation (n7), arts 4, 5, 6.

\(^{48}\) Copyright Designs and Patents Act 1988, s213(4); but it not need to be novel, see \textit{Amoena v Trulife} [1995] 12 D-346

\(^{49}\) \textit{University of London Press v University Tutorial Press} [1916] 2 Ch 601, note also \textit{Infopaq International A/S v Danske Dagblades Forening} (C-5/08) [2009] ECDR 26 regarding possible shift to intellectual creation

\(^{50}\) Copyright Designs and Patents Act 1988, s1(1)(a).

\(^{51}\) Copyright Designs and Patents Act 1988, s4(1)(a).

\(^{52}\) Copyright Designs and Patents Act 1988, s4(1)(c).
differences in the forms of protection which are conferred by each right. Broadly, the patent\textsuperscript{53} and registered design\textsuperscript{54} tests focus on the similarity between products and the scope of the IP right, even if they were independently created. In contrast copyright requires, as the name suggests, copying in a 2D or 3D form, although this can be indirect\textsuperscript{55} (e.g. the person may have forgotten that they saw an existing product which they then build – this raises obvious problems of evidence).

It should be stressed that in contrast with the position in respect of EU Regulation, it is possible for prosthetics to exist without IP. Further, IP rights regarding, say, control of the shape or function of a prosthetic leg, are quite distinct from the ownership of a particular physical prosthetic leg. Where there is a relevant IP right, however, the owner of the IP right will have the power to influence use of the prosthesis made, exactly or similarly, in 2 or 3 D form, to that particular shape or function.\textsuperscript{56} Accordingly, and as is considered further below, the IP owner could forbid the use of a prosthesis without their permission even if the MD regime, the prosthetic user, and the clinical team would like this to be done. And as prosthetics are being further developed and directly sourced by suppliers complementing traditional medical public hospital based structures, (for example by Touch Bionics\textsuperscript{57} and the Alternative Limb Project).\textsuperscript{58}

\textsuperscript{54} Registered Designs Act 1949, s 7(1), Magmatic Ltd v PMS International Group Plc [2016] UKSC 12.
\textsuperscript{55} Copyright Designs and Patents Act 1988, s 16.
\textsuperscript{56} Copyright Designs and Patents Act 1988, s 17(3).
\textsuperscript{57} See Touch Bionics website http://www.touchbionics.com/ (last accessed 13 September 2017).
\textsuperscript{58} See website http://www.thealternativelimbproject.com (last accessed 13 September 2017).
there is the prospect of private control through the power of IP being more visible, rather than hidden behind medical walls.

IP can indeed be relevant to the outputs of all manufacturers and makers. In addition to the growth of private entities, there are community maker voluntary initiatives such as Knitted Knockers for homemade breast prostheses. It will be interesting to monitor the impact of these activities and their attitudes toward IP. Unregistered design and copyright will as seen arise automatically if the thresholds are met, and it is quite possible that the other forms of IP protection will also be sought; whether or not all manufacturers and makers then choose to rely on IP rights to prevent activity by others is their choice. There are examples of this not being done, with patents not being sought and relevant information being made available, to enable the prostheses to be reproduced more readily - including through 3D printing (which was introduced above from its opposite perspective, as providing a new opportunity for infringement). Yet although makers may be open to their work being reproduced by

---


60 For discussion of collaboration, and lessons which can be learnt from the software community in this respect, and drawing on empirical work, see Rosa Maria Ballardini, Juho Lindman and Flores Ituarte “Co-creation, commercialization and intellectual property – challenges with 3D printing” (2016) 7(3) European Journal of Law and Technology Internet; Dinusha Mendis “‘The clone wars’ – episode 1 – the rise of 3D printing and its implications for intellectual property law – learning lessons from the past?” 2013 35(3) European Intellectual Property Review 155-169 and Dinusha Mendis “Clone Wars Episode II – The Next Generation: The Copyright Implications Relating to 3D Printing and Computer-Aided Design (CAD) Files” 2014 6(2) Law, Innovation and Technology 265-281.

some,\textsuperscript{62} what about this being done by a large company seeking to charge high (or any) fees?

The next Section explores the application of the two legal frameworks and their principles on and for prosthetic users and our two core concepts. Throughout, common threads and concerns will be firstly, the holding and exercise of power through development decisions regarding function and aesthetics; and secondly, the control of allocation and limiting of opportunity and choice in different ways. It will be seen that these powers are held by various actors, invariably excluding the prosthesis users themselves on the basis of their own perspectives and priorities.

4 Sensitivity and alignment of the legal frameworks to identity and integrity

4.1 The Medical Devices Perspective

4.1.1 Development and risk

The MD framework addresses a dizzying array of artefacts, from tongue depressors, to scalpels, to arterial stents, to imaging machines and monitors, to implantable cardioverter-defibrillators, and more. Further, although the regulatory framework has direct

application to prosthetics, it takes little specific notice of the nature of the prostheses, or of their impact. The EU Regulation includes ‘modification’, which can be argued to cover ‘extensions of the body’. The framework as a whole appears, however, to view prostheses entirely from a medical perspective, and as having a purely curative or condition-management character.\(^{63}\) The regime fails to engage, therefore, with our notions of identity and integrity as multifaceted constitutive phenomena. There are separate regulations for medical and cosmetic devices,\(^ {64}\) although the EU Regulation notes that the distinction is unclear, and it calls for further action in this respect.\(^ {65}\) Further, the narrow approach to regulation and the prosthesis is taken notwithstanding the standard recital reference to the EU Charter rights - and in this case to dignity, freedom of art and integrity of the person.\(^ {66}\)

Rather, at the heart of the MD framework are the substantive principles of ‘safety’, ‘risk’, and ‘performance’, together with operational principles of ‘transparency’ and ‘proportionality’.\(^ {67}\) The ‘worldview’ of the EU Regulation is argued to be summed up in its instructions that devices must achieve the performance intended by the manufacturer; and also that devices must be designed and manufactured in such a way that, during normal use, they are suitable for their intended purpose – meaning they must be safe and effective, and not compromise the clinical condition or the safety of patients, or the safety

\(^{63}\) See again the definition: EU Regulation (n5), art 2.1(1).
\(^{65}\) EU Regulation (n5), recital 9 and art 1.6.
\(^{66}\) EU Regulation (n5), recital 89.
\(^{67}\) These principles must be read against the imperatives to get products to market quickly and efficiently, and to facilitate the single market: EU Regulation (n5), recitals 1,4,30,31,32,43,44,53,74,87,88,101 and arts 10, 22, 27, 30, 56, 83, 95, 97, 106, 113.
and health of users or, where applicable, other persons.\textsuperscript{68}

With respect to safety, devices are categorised by class, taking into account the purpose of the device as intended by the manufacturer, and the inherent risks of the device,\textsuperscript{69} with criteria for each class set out in the EU Regulation.\textsuperscript{70} The EU Regulation proceeds from an acceptance that absolute safety cannot be achieved, so every device and every act of classification is a matter of risk assessment and risk notification, with risk highlighted everywhere.\textsuperscript{71} A central aim is to minimise the likelihood and consequences of an adverse or harm-causing event, which are approached in the context of medicine and functionality - quite distinct from the points discussed in respect of identity and integrity. Manufacturers must establish and maintain an iterative risk management system applicable to the lifecycle of a device, and must select solutions that result in only “acceptable risks”.\textsuperscript{72} Further, devices must be designed and manufactured in such a way as to reduce as far as possible risks posed by the unintentional ingress of substances into the device, taking into account the following: the device and the nature of the environment in which it is intended to be used;\textsuperscript{73} their physical (i.e., ergonomic) features of the device or external or environmental conditions (i.e., pressure, humidity, temperature,

\begin{footnotesize}
\begin{enumerate}
\item[\textsuperscript{68}] EU Regulation (n5), art 95, 106 (regarding expertise), art I.1 of Annex I, Annex XIV.
\item[\textsuperscript{69}] EU Regulation (n5), art 2.12, 32, 47, 52, 54, 55.
\item[\textsuperscript{70}] See EU Regulation (n5), Annex VIII. For a discussion of some of the then proposed new rules in this respect, see Crom Source White Paper. Changes to EU Medical Device Legislation: What you Need to Know (June 2016) at https://www.cromsource.com/wp-content/uploads/2012/12/Changes-to-EU-Medical-Device-legislation-What-you-need-to-know-White-paper-2016.pdf. Note the prospect of these decisions being open to judicial challenge (also discussed more generally below) – for Scottish example under previous regime see Hyaltech Ltd (Petitioners) [2008] CSIH 64.
\item[\textsuperscript{71}] Many of the specifications relating to labelling and instructions deal with safety and risk: EU Regulation (n5) Chapter I of Annex I.
\item[\textsuperscript{72}] EU Regulation (n5), art 1.2, 1.3, 1.8, 1.9.
\item[\textsuperscript{73}] EU Regulation (n5), art 10.5 of Annex I.
\end{enumerate}
\end{footnotesize}
and mechanical features such as movement, vibration, noise and heat.\textsuperscript{75} Within this, factors impacting on risk include degree of invasiveness, duration of contact, and body system affected.\textsuperscript{76} One can see within this structure that, for the most part, it is manufacturers who set the parameters for performance, normal use, safety, and efficacy, and who undertake the primary risk assessments and design decisions.\textsuperscript{77} The manufacturer will put together a comprehensive dossier with a range of technical evidence determined by the class that the manufacturer considers the device to be within, and this is then submitted to the relevant national Notified Body for assessment and authorisation.\textsuperscript{78} Manufacturers are additionally responsible for ensuring traceability of the device, and follow-up of adverse events.\textsuperscript{79}

\textsuperscript{74} EU Regulation (n5), article 4(a), 7, 14.2(b), Annex I.
\textsuperscript{75} EU Regulation (n5), art 18.5, 19.1, 20.1, 20.2, Annex I.
\textsuperscript{76} EU Regulation (n5), Annex VIII.
\textsuperscript{77} Prior to the reforms of the 1990s, technical standards and specifications were written into regulatory directives. Post-1990s, and largely preserved in the EU Regulation (n5), a separation between law and technical standards was adopted (see e.g. arts 8, 9, 71). Generally, the law relies on essential requirements, as opposed to bespoke technical standards, and the CE mark that is awarded serves as a market entrance authorization, not a rigorous premarket approval of individual products relying on strict product-testing such as in the pharmaceutical sector: Christa Altenstetter “EU and Member State Medical Devices Regulation” (2003) 19 International Journal of Technology Assessment in Health Care 228-248.
\textsuperscript{78} For a good articulation of the previous regulation and the manufacturer’s responsibilities and the approval process in the context of a product liability case based on failure of an implanted prosthetic, see Wilkes v Deput International Ltd. [2016] EWHC 3096 (QB).
\textsuperscript{79} In contrast, traceability and post-market surveillance of devices are addressed in Chapters III and VII respectively of the EU Regulation, and both areas have seen substantial changes. This is in keeping with the strengthening of surveillance in the USA, where the Safe Medical Devices Act 1990 and the Medical Device Amendments 1992 required healthcare facilities to track the use of certain high-risk devices, and to report to the US Food and Drug Administration (FDA) any device-related (serious) injuries or deaths. The FDA subsequently received numerous adverse event reports, including some 160,487 in 2004 alone, with most coming from manufacturers: William Maisel “Safety Issues Involving Medical Devices: Implications of Recent Implantable Cardioverter-Defibrillator Malfunctions” (2005) 294 Journal of the American Medical Association 955-958. See also Frederic Resnic and Sharonlise Normand “Postmarketing Surveillance of Medical Devices—Filling in the Gaps” (2012) 266 New England Journal of Medicine 875-877.
The EU Regulation also provides that any risks which may be associated with use of a device must be evaluated against the benefits to the patient, and the need to achieve a high level of protection of health and safety, taking into account the state of the art.\(^{80}\) The word choice – “patient” - is revealing, although not unexpected given the medical and functional focus noted so far. Thus while this particular provision could provide scope for the opinions and assessment of the individual device user,\(^{81}\) present indications are that this is not coming about. Indeed, whilst much current research on device development in the UK is funded through the National Institute for Health Research (NIHR),\(^{82}\) and patient and public involvement is a prerequisite for NIHR funding,\(^{83}\) much of the existing technology in the healthcare market has not had any prosthetic user engagement in its development other than some involvement of users as recipients of the ultimate product.

Consistent with its worldview discussed above, the EU Regulation states that devices shall be designed and manufactured in such a way that they perform appropriately for their intended purpose taking into account the skills and the means available to

\(^{80}\) EU Regulation (n5) art I.1 of Annex I; and proportionality is meant to inform this calculus: EU Regulation (n5) art 10.9. Related to safety and risk, manufacturers must establish and maintain a quality management system and an iterative risk management system applicable to the lifecycle of a device, and must select solutions that result in only acceptable risks: EU Regulation (n5), art 1.3, 5.5 and art 1 of Annex I.


\(^{83}\) And see eg NIHR “Patients and the public” webpage [https://www.nihr.ac.uk/patients-and-public/](https://www.nihr.ac.uk/patients-and-public/) (last accessed 13 September 2017).
laypersons, and the influence resulting from variation that can reasonably be anticipated in the layperson’s technique and environment. Rather like the reference to the “patient” above, this could provide a base for a deep interrogation of “environment” drawing on our two core concepts. The main requirements for action in this respect, however, involve information: instructions provided by the manufacturer shall be easy for the lay person to understand and apply, and labels are not to contain false or misleading information about the device’s purpose, use, or performance. So again, the user is viewed as a passive beneficiary and involvement of lay persons to any extent is not mandated. This is particularly interesting in the context of “repairs”. A prosthetic limb might need repair or replacement, not least because of natural degradation and development of the rest of the body. Decisions in this respect, however, are much more (or wholly) under the control of the prescriber of the prosthesis than the user.

This regulatory regime, at its extremes, can lead to the non-user having the power (and the responsibility) to make decisions about functionality without any regard to the aspirations of the user, or indeed regarding aesthetics. This will have an impact on identity - one which is so far unexplored in the existing discussion of bodily autonomy. And it is perhaps as a result of this marginalisation (with respect to design, function, performance, and many other relevant details) that more informal maker movements have arisen, such as those discussed above. The EU Regulation can apply to any prosthesis, howsoever developed, but devices manufactured and used within health institutions are

---

84 EU Regulation (n5), arts 18.1 and 22.1 of Annex I.
85 EU Regulation (n5), art 7,
87 Note focus on abortion and euthanasia, eg Wicks (n3) 1 et seq.
considered as being ‘put into service’. They are therefore exempt from many requirements of the EU Regulation, although they must still comply with general safety and performance requirements. Nonetheless, given this reality, it is important to consider how devices are delivered to people, which means considering their provision within the UK’s National Health Service (“NHS”).

4.1.2 Delivery of prosthetics: practical, financial and judicial

There are 44 centres in the UK as a whole which provide prosthetic services. Each centre provides a service for the surrounding population as defined by the commissioning arrangements that operate in each of the countries in the UK. These centres run very similar programmes and offer a range of prostheses based on nationally agreed guidelines, although some services, such as children’s prosthetics, are only available from the larger, more specialised centres. Most centres adopt a multidisciplinary team approach, with a rehabilitation physician, physiotherapist, occupational therapist, psychologist, and prosthettist all available to the prosthetic user, depending on their needs.

---

88 EU Regulation (n5), article 5.4; such devices cannot be transferred to another legal entity: Article 5.5a EU Regulation.
89 EU Regulation (n5), article 5.
Taking the NHS in England and Wales as an example, patients are referred to a prosthetic limb fitting centre by a clinician, generally a physiotherapist, or the surgeon who performed the amputation. At the prosthetics centre, the first assessment is whether the patient is suitable for a prosthesis – many patients are frail or may not have walked for a considerable period of time due to another medical condition, such as heart disease. After an initial trial in the centre with a highly adjustable generic prosthesis, the decision to proceed to manufacturing a prosthesis is made. This matches the shape of the residual limb (the “stump”), accommodating any wounds or scars on the skin, and is designed to take the forces through it commensurate to the use of the limb – in this case walking or activities involving the arm. The limb will comprise the socket (the interface between the user’s skin and the prosthesis – generally a rigid polypropylene shell), limb components (flexible joints, shock absorbers) and a cover (foam, nylon, silicone) that provides the cosmesis.

The decision on the exact composition of the limb is reached by the team in the centre in consultation with the prosthetic user. Whilst a person with a newly acquired amputation would only rarely be familiar with prosthetic technology, their opinions on the appearance of the prosthesis and the required functions would be taken into account when formulating the prescription. These would, of course, be tempered by the knowledge and experience of the clinical team. The specifics of this “prescription”

---

93 Account provided by O’Connor, expert in this field and Charterhouse Professor of Rehabilitation Medicine, University of Leeds and Honorary Consultant Physician in Rehabilitation Medicines at Leeds Teaching Hospitals NHS Trusts
94 See also discussion of the process and the different roles played in a tax case General Healthcare Group Ltd v The Commissioners for Her Majesty’s Revenue & Customs [2014] UKFTT 1087 (TC) and on appeal [2016] UKUT 315 (TCC).
will change over time depending on the evolving needs of the user. Minor repairs or modifications can be performed in a day at the centre, but more extensive alterations will require a new prescription and the manufacture of a new limb. Critically, the NHS and the private sector can often come together. Each centre is associated with one of the major manufacturers and their products will be the preferred starting components for the service. Prosthetic users should, however, be offered the most appropriate components for their needs, irrespective of whether the manufacturer linked to the centre supplies that component.

From the above, it should be clear that the question of “need” is central. Its meaning, however, is not at all clearly or consistently understood, and uncertainty persists with respect to how it is or sought to be applied given current legal framework and the prevailing resource context. At the time of writing (2017-18), a user’s desire to have a limb that enables them to pursue a specific activity (e.g. swimming) will be problematic, as this will not normally be deemed a ‘health need’. Interestingly, experiences in this respect will vary, as our interviews and focus group meetings with prosthetic users\(^\text{95}\) indicate. Our evidence suggests that firstly some users are more proactive and engaged than others; secondly, some users (typically those with more education, greater language skills and experience that lead to recognition of expertise such as dancers and athletes), are likely to have more regard paid to their interests and opinion; and thirdly, some teams are more open to users as development partners than others. All of this means that experiences within the NHS will not be uniform.

\(^{95}\) See note 4 regarding method.
Nonetheless, a strong theme from all users is that they would like greater regard to be had to their interests.

The above raises a further issue, namely that of funding. As with other healthcare services in the UK, a small number of individuals choose to purchase a prosthesis and the associated service from a private provider (such as those discussed above). In some cases this may be funded by an insurance company if the amputation was related to, say, a motor vehicle collision. Within the NHS, as with other NHS services, provision of prosthetics is free at the point of service. Actors within the NHS will have to make difficult funding decisions and guidelines are issued from time to time in this respect. As an example, the NHS 2016 Funding Guidelines for England provide that prosthetics for lower limb loss are likely to be routinely funded.\(^\text{96}\) Of course, there is scope for legal challenge to funding decisions by public bodies (such as prosthetic centres) through the process of judicial review,\(^\text{97}\) provided the applicant has sufficient interest in the matter,\(^\text{98}\) and resources to pursue it. The challenge will need to be on the basis, broadly, that the decision is irrational and follows unfair or unlawful policies or that proper process has not been followed - rather than raising any questions of substance. Decision in cases involving the funding of cancer treatments\(^\text{99}\) and of breast augmentation for transsexuals\(^\text{100}\) demonstrate how difficult it can be to achieve

\(^{96}\) See NHS England “NHS England announces provisional investment decisions for specialised services (11 July 2016) https://www.england.nhs.uk/2016/07/spec-services-investment/ (last accessed 13 September 2017). This is subject, in a reminder of the limited resource, to decisions regarding HIV funding.

\(^{97}\) See eg Association Provincial Picture Houses Ltd v Wednesbury Corp [1948] 1 KB 223.

\(^{98}\) English approach – see section 31(3) Senior Courts Act 1981 – includes a requirement of obtaining the consent of the court.


\(^{100}\) R (app C) v Berkshire West PCT [2010] A.C.D. 75, 2020 EWHC 1162 (Admin).
success in the judicial review process. Even if success is achieved, this means that the original decision maker will have to reconsider of the decision on the different bases, not that they will necessarily arrive at a different substantive result.

This discussion of judicial review raises two further points. Firstly, as the cancer treatment case made clear, the primary care trust policy can provide that there could be exceptional circumstances, with funding able to go beyond what is in the policies. This was to be assessed, however, on the basis of legitimate clinical needs, not on personal characteristics or desires falling outside clinical care needs. This reiterates the themes identified above with respect to the perspectives which are privileged in MD regulation, and it further entrenches the non-user centric approach seen above to be adopted in practice. It is therefore another worrying confirmation that law and regulation applicable to prosthetics do not engage with the user or with the core concepts of integrity and identity. Secondly, judicial review has its limits. The fact that, say, a prosthetic user is unable, through whatever means, to afford a creative and frankly fabulous graphite and jewelled leg supplied directly by the Alternative Limb Project could not lead to a challenge on this basis. From the perspective of public law and limited budgets this might seem appropriate; when viewed through the lens of perceptions of self and opportunities for expression and actualization (and their link to wellbeing), a different position is argued to emerge.

In summary, it is the manufacturer, the clinician and other health professionals who are expected to make most decisions, and they are expected to act in advancement of medical principles and sensibilities, and in compliance with the EU Regulation and
other guidelines and restrictions. There is no sense of acknowledgement from the legal, regulatory, or funding perspective that a device (here the prosthesis) may be important to the individual’s identity. Indeed, this concept is hardly implicated formally other than through the framework’s attention to performance and risk, although speak indirectly to integrity. All matters and parameters are informed by the manufacturer and medical perspectives, and all risk assessments and measures are tailored to those (often conjoined) ideals. There is no direction that these standards must have any relevance to the lived experience of the user. A rather different silence and disengagement can be found when one explores the impact of IP law on identity and integrity for prosthetics users.

4.2 The IP perspective

In addition to the basic thresholds to be met for IP rights to exist, there are some more specific provisions which may be relevant to prosthetics. Firstly, there is controversy as to when a software-related innovation can be the subject of a patent\textsuperscript{101} (bearing in mind that it can always be the subject of copyright, although this has the more limited form of protection, as discussed above). This restriction could be relevant to software innovation relating to the preparation of prosthetics and the gathering of data sets which enable prostheses to be prepared for individual users based on accumulated data from other users. It is also interesting to note, given discussion regarding the extent to which prostheses may be viewed by users as part of the body, that EU and the resulting UK legislation limits the patenting of biotechnological innovation, notably those which

\textsuperscript{101} European Patent Convention, art 52(2) and (3); and Patents Act 1977, s 1(2); \textit{Programs for Computers Case} G03/08 (Enlarged Board of Appeal) [2010] EPOR 36; \textit{Symbian Ltd v Comptroller General of Patents, Designs andTrademarks} [2008] EWCA Civ 1066.
involve the use of human embryos for industrial or commercial purposes. This area of law has seen controversies regarding the extent to which courts have been willing to engage with morality and ethics, again raising a marked difference between “artificial” and “real” parts of the body.

Within this framework, if IP rights exist in respect of a prosthesis, they will, as indicated above, confer power on the IP owner regarding use of the underlying subject matter (the shape of the prosthetic leg, say). This is confined, however, to carrying out specific acts - particularly making and selling (but importantly for patents, not repairing which is quite distinct) - during the currency of the term of the right. IP rights will expire across a varying landscape of dates, from 3 years for a Community unregistered design right to the life of the author plus 70 years in the case of the copyright in the


104 United Wire v Screen Repair Services (Scotland) Ltd [2000] 4 All E.R. 35
drawings for a prosthetic limb). There must also be infringing activity in a country where there is an IP right. This may become relevant if, say, a user moves from the UK to France.

A key point here is that if there is a relevant right and activity, then IP owners have no legal responsibility to pay any attention to the impact of their decisions on prosthetic users. There are some exceptions to IP infringement, however, and a key opportunity in respect of patents involves private and non-commercial use. This may become highly relevant as 3D printing technologies become more widespread and cost effective, and there may be an increase in users making their own limbs by reproducing prostheses which are the subject of another’s patent.

There is a possibility, therefore, of IP law having a restrictive impact on choices made by and (largely) for prosthesis users. This increases when it is considered that developers of prosthetic limbs are indeed engaging with IP rights. There are patents, for example for a prosthetic device made of a particular plastic material (US3908201A from 1972), and also cases involving patents for silicon foam for covering prostheses for implanting in the body. There are registered designs, for example for a slideable and rotatable coupler for a prosthetic leg (UK D462767 from 2001). Copyright and

---

105 UK - copyright life plus 70 Copyright Designs and Patents Act 1988, s 12; UK unregistered design right 15 years with licence of right for last 5 Copyright Designs and Patents Act 1988, s216; 20 years patent Patents Act 1977, section 25; registered community design term sets of 5 years up to 25 years and unregistered community design rights 3 years Community Design Regulation (n7), arts 11, 12.


108 McGhan Medical UK Ltd v Nagor Ltd (2001) 24(7) IPD 240043
unregistered designs cannot be evidenced in the same way (given their more informal nature of creation), but there are examples of infringement actions being raised. Notably, a court rejected an argument\textsuperscript{109} that because of the so-called “must fit” provision in UK unregistered design law,\textsuperscript{110} there was no protection for the shape of a breast prosthesis. The court found that although the shape of the bra might influence the shape of the breast prosthesis, a bra shape did not determine the detail or circumstances of it – indeed, the prosthesis would fit several bras.

At present, there are no accounts of IP rights being an obstacle to prosthetic provision in the NHS. If there is greater use of 3D technology, and more privately funded prosthetic provision outside the NHS, then IP may become a more immediate issue. This would then provide yet another area of challenge to the short term private power conferred by IP;\textsuperscript{111} and also to the conventional position that this should be accepted given the argument that IP encourages innovation and creativity, dissemination of the results and investment in the process, to the longer term benefit to all.\textsuperscript{112}

In summary, IP is an opportunity to be pursued by those who innovate and create in prostheses, looking across both the functional and the aesthetic. When

\begin{footnotesize}
\begin{itemize}
\item[\textsuperscript{109}] Amoena v Trulife [1995] 12 D-346
\item[\textsuperscript{110}] Copyright, Designs and Patents Act 1988, s213(3)(b)(i).
\end{itemize}
\end{footnotesize}
assessed in the present context, the development of new prostheses which may be encouraged by and lead to IP rights, can indeed have positive outcomes for society and for individual users as they pursue ways of displaying and developing their varied interests and choices. This can assist in engaging with identity/identities and integrity. However, the discussion so far has shown that this is a hope, not a mandate outcome. Further, those owning IP rights are by international treaty-informed domestic legislation, entitled to object to uses and to raise a court action, such as those discussed above. Exercising this power can be costly and time-consuming, and as has been discussed, the IP owner may be vulnerable on various points regarding infringing activity, term or a relevant exception. Yet the other party is confronted with the problem of facing the action – and looking forward, this could influence decision-making in allocation of prosthetic limbs.

4.3 Control and Authority for Prosthetics – Reflections

The above analysis of the legal and regulatory frameworks for MD and IP, combined with the results of our research interviews and focus groups, reveal that the power to determine the nature and limitation of which prosthetic limb that will be issued (including for example, whether it might be suited to swimming or rock-climbing), does not sit with the user, and does not always even involve the user. Even if the desire is

identified and supported, insufficient budget can frequently frustrate the realisation of the desire. One research interview also indicated that private fundraising (one way of addressing this outside the NHS) can be perceived by prosthetic users as leading to a prosthesis which belongs more to the donors, so this route might be even less aligned with the user’s identity and integrity. Further, if a particular prosthesis which supports identity and integrity (e.g. running, climbing, decoration) is able to be allocated, an IP owner can restrict or prevent this. The identity/identities and integrity of the prosthetic user are not matters which are stipulated as relevant for those with authority and control in these decisions. Rather, there are obligations and restrictions under NHS funding rules and the EU Regulation, and rights held by others under IP legislation.

Steps could be taken to change these regimes. In IP, a special exception could be created relating to prosthetic users and 3D printing for copyright, designs, and patents. This would reflect debates ongoing elsewhere in IP with respect to users’ rights, such as parody.115 Analogies could also be drawn from changes to IP law to enable greater and more accessible use of works by people with disabilities – e.g. conversion into Braille or audio versions - as can be seen from national and international developments.116 Another opportunity might to be create a prosthetic specific licensing regime117 which could avoid prosthetic users being declined particular opportunities on the basis of disputes over cost – whether funding is being provided

115 See EU consideration of parody in Deckmyn v Vandersteen (C-201/13) [2014] Bus. L.R. 1368.
117 See Copyright Designs and Patents Act 1988, chapter VII.
personally, privately or through the NHS. Another pathway is to argue for change within the MD regulatory framework so that greater regard for the lives, aspirations, and views of users are mandated when assessing questions of need and health. This could build on the identification in the EU Regulation for exploration of the link between medicinal and cosmetic, as discussed above. Aligned with this, a third pathway would be to argue for a wider approach to need within the NHS policy and budgetary frameworks. These three approaches, taken together, would address specific issues and go some way to addressing the disregard of the person, that is apparent in two key legal and regulatory regimes. They could also instigate a movement to delivering new approaches to authority and control, to identity and integrity, and to the person.

5. Conclusions

Like the physical states to which they are applied, prosthetic limbs can challenge our perception of what it means to be human, to be a person. They can challenge our symbolic order, or the binary categories and differentiations that we use to structure society (such as nature/construct, human/non-human, self/other, friend/stranger). Indeed, they may offer new categories and measures, and new possibilities and capabilities. Yet their provision and usage are characterised by social, legal and ethical debates around risk, boundaries, and power. The result is often a collage, or indeed a cacophony, rather than a consensus of values, visions, and decision-making models associated with specific interventions or technologies. And all of this is positioned against a legal landscape

119 Tsjalling Swiersta and Arie Rip “NEST-Ethics: Patterns of Moral Argumentation about New
which fails to engage (at least sufficiently) with the person, and the concepts of identity and integrity.

More specifically, our preliminary findings from doctrinal research are that the current MD and IP frameworks, both of which are relevant to prosthetic limbs, adopt a decidedly internally focused perspective. Accordingly, the principles of each field are more important as shaping concepts than those deemed important (for meaning-making) by the prosthetics community, insofar at least as we have engaged with them. Generally, inadequate direct or effective regard is had to the impact of legal approaches and decisions on the user from both an existential and a practical perspective. Additionally, the regimes are insufficiently joined up, though they share an over-reliance on largely unexamined understandings of the ‘normal’ and lack of engagement with others.

MD and IP focus on shaping particular activities aimed at solving particular problems. Key drivers are safety and functionality on the one hand, and money/commerce and reward (with some unfocussed regard to public benefit) on the other. Each of these has their own control and authority structures and there is limited space for user views or participation, and no focus on the core of the person and what the person could aspire to become. Regarding MDs, it is tempting to argue that when seeking to deliver patient safety and to manage risk, there is no place for a focus on, or indeed engagement with, the core concepts and their legal reflections. But this ignores
the arguments put forward here; it accords greater weight to the values of one legal and value system than to another, and stresses economics rather than enabling the pursuit of the identity and choice of the user – that is, their wellbeing. Further, this accords power to those who have traditionally held it – doctors, the NHS, managers, IP owners and corporate manufacturers - rather than to users. An approach which is more open to users may not appeal to all users; not all may wish to exercise their choice. Yet this does not mean that the opportunity, together with structures which could embed wider regard for user groups (both locally, in each centre for the benefit of users of that centre, and nationally, such as the All-Party Parliamentary Limb Loss Group who advocate for amputees throughout the UK), should not be pursued.

We conclude that there is a need for a new fair and holistic landscape for multi-faceted decision-making regarding extensions to the person. In addition to delivering a new approach to decision-making by clinicians, budget setters, and IP owners, this should enable more attention to be paid by lawyers, policymakers, and other actors to issues, values, and ambitions shared by users, and also to the essential relevance of the person. In turn, this would support identity and integrity. At the moment, law fails to support effective practical delivery of prostheses or theoretical approaches to the person. This inadequacy cannot continue. The suggestions made above regarding more exceptions to IP and a broader perspective in MD regulation can, as indicated, assist. But the issue is wider. One of the aims of this Wellcome Trust funded research is to encourage scholars, policymakers, industry, and others to think about body extensions not as functional tools or attachments, but as profound elements of identity in a way similar to race, gender and orientation. To inform and justify this, and to further identify areas for new issue specific regulation, much would be gained from greater
recognition of empirical evidence from the field/users and from the undertaking of more such research. This could include research and engagement with the maker movement which better acknowledges the creative component of prosthetics, the pursuit of excellence, and the human flourishing that is realised or frustrated by those with prosthetic limbs. This would be a decisive change in perspective – the creation of a new normality and approaches to control and authority, discarding the restrictions and tyranny of the narrow older one, and one which will ultimately combines law, practice, business and users of prosthetics in a fairer way. Pursuing this research, and how best to deliver this goal, is the objective of the authors.